SEARCH

SEARCH BY CITATION

Keywords:

  • mesothelioma;
  • irinotecan;
  • cisplatin;
  • mitomycin C;
  • phase II;
  • first-line;
  • recurrence

Abstract

BACKGROUND.

Malignant pleural mesothelioma (MPM) is a rapidly progressive lethal tumor. Treatment options remain limited and the outcome in recurrent disease is poor.

METHODS.

A Phase II open-label noncomparative study was conducted to assess the safety and efficacy of the triplet combination irinotecan, cisplatin, and mitomycin-C (IPM) chemotherapy in untreated patients and in those with previous exposure to chemotherapy.

RESULTS.

In 62 patients an objective response rate of 25% was observed. In the first-line setting progression-free survival measured 6.4 months (95% confidence interval [CI]: 4.5–7.3) and overall survival was 10.8 months (95% CI: 7.9–13.7). In the second-line setting progression-free survival was 7.3 months (95% CI: 3.4–11.2) and overall survival was also 7.3 months (95% CI: 4.8–9.8). Psychosocial well-being improved during chemotherapy and the main toxicity observed was neutropenia (40%).

CONCLUSIONS.

IPM appeared to have a reasonable response rate with an acceptable toxicity profile in the first- and second-line treatment of MPM. Cancer 2007. © 2006 American Cancer Society.